Replies to post #796495 on NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

You’re right about one thing: surviving a 90% drawdown takes conviction. But here’s what that conviction funded:

-- A multi-country, double-blind, placebo-controlled Phase 3 trial—executed across the U.S., U.K., and Germany.

-- Peer-reviewed publication in JAMA Oncology that determined that OS was statistically significant for nGBM and rGBM.

In this study, adding DCVax-L to SOC was associated with a clinically meaningful and statistically significant improvement in median OS for patients with both nGBM and rGBM compared with matched, contemporaneous external controls.

-- Independent validation of survival benefit in nGBM and rGBM.

-- Full-scale submission to MHRA for regulatory review.

-- A robust patent estate, recently expanded via Roswell Park’s Dendritic Cell Research Center—who licensed five new patent families to NWBO for no upfront payment. Are they “bag holders” too, or do they see what’s coming?

--Eden platform scalability, enabling NWBO to manufacture personalized DCVax-L doses at scale—automated, inspectable, and GMP-compliant.

If that’s what ‘bag holders’ build, I’ll wear the label proudly. Because while you’re laughing, we’re launching. But you know we are NOT bag holders. We all know exactly what we hold, which is why there's a 24/7 all-out effort to convince us otherwise.

You will lose, we will win.